Stay updated on Pembrolizumab in EOC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in EOC Clinical Trial page.

Latest updates to the Pembrolizumab in EOC Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedAdded a Locations section with Florida as a location and removed the separate Florida Locations entry; the HHS Vulnerability Disclosure link was removed. Revision tag updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision information updated from v3.3.1 to v3.3.2 in the page footer, with no impact on study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision: v3.3.1 is now shown, replacing v3.2.0. This appears to be a minor version update with no substantive changes to the study details or eligibility information.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page no longer displays the government funding status notice related to potential delays and operating status.SummaryDifference0.4%

- Check61 days agoChange DetectedResults for NCT02834975 have been posted with updated outcomes and safety data, and enrollment/completion dates have been revised in the Study Details.SummaryDifference0.4%

- Check90 days agoChange DetectedSummary: The page adds a government-operating-status notice and new v3.2.0 version tag, while removing the old v3.1.0 tag.SummaryDifference3%

Stay in the know with updates to Pembrolizumab in EOC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in EOC Clinical Trial page.